Study of cabozantinib after initial treatment for osteosarcoma
Part of Cancer clinical trials.
This trial tests whether a new drug (called cabozantinib) can help keep osteosarcoma from coming back after initial treatment. It is for people who have completed their first round of therapy and have no sign of active cancer or only stable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of high-grade osteosarcoma (a type of bone cancer that is not low-grade).
- You need to have finished your first set of treatments (surgery, chemotherapy, or radiation) for the primary tumor and any spread.
- You should be 4 years old or older and able to swallow tablets.
- Your cancer should be either in complete remission (no sign of it) or have only stable remaining disease that isn't growing.
- You must be generally fit and have adequate heart, kidney, liver, and blood counts as checked by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This research study follows young people newly diagnosed with osteosarcoma (a type of bone cancer) who are receiving standard chemotherapy. Researchers will collect information about how the cancer responds to treatment and study biological samples to better understand the disease.
This Phase 2 trial studies whether combining pembrolizumab and cabozantinib can control advanced sarcoma that can’t be removed by surgery and has grown or returned after standard treatment. It may help shrink tumors and improve outcomes in adults who have limited treatment options left.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.